Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Screening for Demodex blepharitis: Integrating best practices into routine eye care | Ophthalmology Times
(Image Credit: AdobeStock) Demodex blepharitis is more common than previously thought, and proper diagnosis and management are important for effective patient care. Anne M. Zaki, MD, a cornea specialist in private practice at Desert Eye Specialists in Peoria, Arizona, moderated…
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all key data required to support the submission of New Drug Applications (NDAs) in the US and China for NCX 470.1 NCX 470 is Nicox’s lead clinical product candidate…
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Management and Monitoring Strategies in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy | Ophthalmology Times
(Image Credit: AdobeStock/9dreamstudio) Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a polysialic acid-coated nanoparticle in which the polysialic acid…
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Ophthalmology Times
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase 2 dose-ranging trial (NCT06164587) for its dual inflammasome inhibitor, K8, for geographic atrophy (GA). K8 is a member of a new class of inflammasome-inhibiting drugs called Kamuvudines. They…
Phase 1 trial confirms safety and tolerability of Huons’ dry eye therapy | Ophthalmology Times
(Image Credit: AdobeStock) Huons Co, a pharmaceutical subsidiary of Huons Group, received phase 1 Clinical Study Results (CSR) for HUC1-394, an eye drop for the treatment of dry eye disease (DED). HUC1-394 is a peptide-based eye drop for dry eyes,…
Kiora Pharmaceuticals receives patent for additional and novel formulations of KIO-100 compounds | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of the KIO-100 family of compounds from Kiora Pharmaceuticals. In July 2025, the company announced it had…